Analogs of the novel phytohormone, strigolactone, trigger apoptosis and synergize with PARP inhibitors by inducing DNA damage and inhibiting DNA repair

Strigolactones are a novel class of plant hormones produced in roots that regulate shoot and root development. We previously reported that strigolactone analogs (SLs) induce G2/M cell cycle arrest and apoptosis in a variety of human cancer cells and inhibit tumor growth of human breast cancer xenografts in mice. SLs had no significant influences on non-transformed cells. Here we report for the first time that SLs induce DNA damage in the form of DNA double-strand breaks (DSBs) and activate the DNA damage response signaling by inducing phosphorylation of ATM, ATR and DNA-PKcs and co-localization of the DNA damage signaling protein, 53BP1, with γH2AX nuclear foci. We further report that in addition to DSBs induction, SLs simultaneously impair DSBs repair, mostly homology-directed repair (HDR) and to a lesser extent non-homologous end joining (NHEJ). In response to SLs, RAD51, the homologous DSB repair protein, is ubiquitinated and targeted for proteasomal degradation and it fails to co-localize with γH2AX foci. Interestingly, SLs synergize with DNA damaging agents-based therapeutics. The combination of PARP inhibitors and SLs showed an especially potent synergy, but only in BRCA1-proficient cells. No synergy was observed between SLs and PARP inhibitors in BRCA1-deficient cells, supporting a role for SLs in HDR impairment. Together, our data suggest that SLs increase genome instability and cell death by a unique mechanism of inducing DNA damage and inhibiting DNA repair.

[1]  H. Koltai Cellular events of strigolactone signalling and their crosstalk with auxin in roots. , 2015, Journal of experimental botany.

[2]  R. Yarden,et al.  Strigolactone analogs act as new anti-cancer agents in inhibition of breast cancer in xenograft model , 2015, Cancer biology & therapy.

[3]  M. Kumar,et al.  Strigolactone signaling in root development and phosphate starvation , 2015, Plant signaling & behavior.

[4]  Ilya Shmulevich,et al.  Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. , 2015, Journal of the National Cancer Institute.

[5]  M. Kastan,et al.  Repair versus Checkpoint Functions of BRCA1 Are Differentially Regulated by Site of Chromatin Binding. , 2015, Cancer research.

[6]  O. Leyser,et al.  Strigolactone signalling: standing on the shoulders of DWARFs. , 2014, Current opinion in plant biology.

[7]  H. Koltai Receptors, repressors, PINs: a playground for strigolactone signaling. , 2014, Trends in plant science.

[8]  Chin-Lee Wu,et al.  The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells , 2014, Oncotarget.

[9]  Hans Clevers,et al.  Organoid Cultures Derived from Patients with Advanced Prostate Cancer , 2014, Cell.

[10]  S. Baylin,et al.  Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. , 2014, Molecular cell.

[11]  D. Reglodi,et al.  PACAP27 is Protective Against Tat-Induced Neurotoxicity , 2014, Journal of Molecular Neuroscience.

[12]  R. Yarden,et al.  Strigolactone analogues induce apoptosis through activation of p38 and the stress response pathway in cancer cell lines and in conditionally reprogramed primary prostate cancer cells. , 2014, Oncotarget.

[13]  Matthias Dobbelstein,et al.  Targeting tumour-supportive cellular machineries in anticancer drug development , 2014, Nature Reviews Drug Discovery.

[14]  Michal Zimmermann,et al.  53BP1: pro choice in DNA repair. , 2014, Trends in cell biology.

[15]  C. Albanese,et al.  Radiation induces diffusible feeder cell factor(s) that cooperate with ROCK inhibitor to conditionally reprogram and immortalize epithelial cells. , 2013, The American journal of pathology.

[16]  R. Yarden,et al.  BRCA1 targets G2/M cell cycle proteins for ubiquitination and proteasomal degradation , 2013, Oncogene.

[17]  R. Livingston,et al.  Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review. , 2013, The oncologist.

[18]  Phang-lang Chen,et al.  A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia , 2013, EMBO molecular medicine.

[19]  M. Papa,et al.  BRCA1-dependent Chk1 phosphorylation triggers partial chromatin disassociation of phosphorylated Chk1 and facilitates S-phase cell cycle arrest. , 2012, The international journal of biochemistry & cell biology.

[20]  Peter Bouwman,et al.  The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance , 2012, Nature Reviews Cancer.

[21]  T. Taniguchi,et al.  MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition. , 2012, Cancer research.

[22]  H. Joenje,et al.  Diagnosis of Fanconi Anemia: Chromosomal Breakage Analysis , 2012, Anemia.

[23]  Chris Albanese,et al.  ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. , 2012, The American journal of pathology.

[24]  A. Ashworth,et al.  The DNA damage response and cancer therapy , 2012, Nature.

[25]  L. Symington,et al.  Double-strand break end resection and repair pathway choice. , 2011, Annual review of genetics.

[26]  B. Kaina,et al.  Rad51 and BRCA2 - New Molecular Targets for Sensitizing Glioma Cells to Alkylating Anticancer Drugs , 2011, PloS one.

[27]  Yun-Wei Lin,et al.  Down-Regulation of Rad51 Expression Overcomes Drug Resistance to Gemcitabine in Human Non–Small-Cell Lung Cancer Cells , 2010, Journal of Pharmacology and Experimental Therapeutics.

[28]  E. Alli,et al.  Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. , 2010, Cancer research.

[29]  J. Settleman,et al.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer , 2010, Oncogene.

[30]  Y. Kapulnik,et al.  Strigolactones are positive regulators of light-harvesting genes in tomato , 2010, Journal of experimental botany.

[31]  Yan Geng,et al.  Role of DNA in condensation and combinative self-assembly. , 2010, Chemical communications.

[32]  Yves Pommier,et al.  The complexity of phosphorylated H2AX foci formation and DNA repair assembly at DNA double-strand breaks , 2010, Cell cycle.

[33]  T. Chou Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[34]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[35]  D. Schild,et al.  Overexpression of RAD51 suppresses recombination defects: a possible mechanism to reverse genomic instability , 2009, Nucleic Acids Research.

[36]  Y. Pommier,et al.  DNA cleavage assay for the identification of topoisomerase I inhibitors , 2008, Nature Protocols.

[37]  H. Klein,et al.  The consequences of Rad51 overexpression for normal and tumor cells. , 2008, DNA repair.

[38]  F. Alt,et al.  Distinct roles of chromatin-associated proteins MDC1 and 53BP1 in mammalian double-strand break repair. , 2007, Molecular cell.

[39]  Dihua Yu,et al.  Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation , 2007, Molecular Cancer Therapeutics.

[40]  Alan Ashworth,et al.  Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. , 2006, Cancer research.

[41]  F. Couch,et al.  Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. , 2006, Molecular cell.

[42]  Jiri Bartek,et al.  Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks , 2006, The Journal of cell biology.

[43]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[44]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[45]  Jiri Bartek,et al.  Chk1 and Chk2 kinases in checkpoint control and cancer. , 2003, Cancer cell.

[46]  Lawrence C. Brody,et al.  BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage , 2002, Nature Genetics.

[47]  Ashok R Venkitaraman,et al.  Cancer Susceptibility and the Functions of BRCA1 and BRCA2 , 2002, Cell.

[48]  B. Modan,et al.  Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Jeremy M. Stark,et al.  Double-strand breaks and tumorigenesis. , 2001, Trends in cell biology.

[50]  H. Stürzbecher,et al.  Over‐expression of wild‐type Rad51 correlates with histological grading of invasive ductal breast cancer , 2000, International journal of cancer.

[51]  V. Yamazaki,et al.  A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage , 2000, Current Biology.

[52]  H. Stürzbecher,et al.  DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma , 2000, Oncogene.

[53]  Y. Pommier,et al.  Induction of topoisomerase I cleavage complexes by 1-beta -D-arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Y. Pommier,et al.  Induction of Reversible Complexes between Eukaryotic DNA Topoisomerase I and DNA-containing Oxidative Base Damages , 1999, The Journal of Biological Chemistry.

[55]  P. Baumann,et al.  Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. , 1998, Trends in biochemical sciences.

[56]  S. Vispé,et al.  Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. , 1998, Nucleic acids research.

[57]  M. Jasin,et al.  Homology-directed repair is a major double-strand break repair pathway in mammalian cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[58]  A. Ashworth,et al.  Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation , 1997, Nature Genetics.

[59]  K. Khanna,et al.  Targeting homologous recombination, new pre-clinical and clinical therapeutic combinations inhibiting RAD51. , 2015, Cancer treatment reviews.

[60]  C. Beveridge,et al.  Diverse roles of strigolactones in plant development. , 2013, Molecular plant.

[61]  A. McCullough ROCK Inhibitor and Feeder Cells Induce the Conditional Reprogramming of Epithelial Cells , 2013 .

[62]  J. Stark,et al.  I-SceI-based assays to examine distinct repair outcomes of mammalian chromosomal double strand breaks. , 2012, Methods in molecular biology.

[63]  F. Zunino,et al.  In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems , 1998, Cancer Chemotherapy and Pharmacology.

[64]  D. Kern,et al.  In vitro pharmacodynamics of 1-beta-D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum(II). , 1988, Cancer research.